Skip to content
Review Open access

Efficacy and safety of short (≤6 months) versus prolonged (>6 months) dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis

Oct 2026 · European Heart Journal · 0 citations

Abstract

The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains uncertain, as therapy must balance ischemic protection against bleeding risk. While prolonged DAPT may enhance antithrombotic efficacy, shorter regimens have been proposed to improve safety. To compare the efficacy and safety of short (≤6 months) versus prolonged (>6 months) DAPT following PCI. PubMed, Embase, and Cochrane Library were systematically searched from inception through November 27, 2025. Randomized controlled trials and observational cohort studies comparing short versus prolonged DAPT were included. Efficacy outcomes were all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), and target-vessel revascularization (TVR). The primary safety outcome was bleeding. Pooled risk ratios (RRs) were calculated using random-effects models, with heterogeneity assessed by the I² statistic. Thirty-three studies (24 RCTs and 9 cohorts), including 86,676 patients, were analyzed. Short DAPT showed comparable efficacy to prolonged DAPT, with no significant differences in all-cause mortality, cardiovascular mortality, MACE, or TVR. Short DAPT significantly reduced bleeding events (RR 0.86, 95% CI 0.76–0.98; p=0.02) with no heterogeneity (I²=0%). In patients undergoing PCI, ≤6 months of DAPT provides similar protection against ischemic events as >6 months, while significantly reducing bleeding. These findings support guideline-aligned strategies favoring shorter DAPT in appropriately selected patients, particularly those at higher bleeding risk, without compromising cardiovascular outcomes.OutcomesINFOGRAPHIC

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.